By Inti Landauro
PARIS--French pharmaceutical giant Sanofi SA (SAN.FR) Wednesday said it teamed up with closely held Myokardia to develop therapies for genetic heart diseases, called cardiomyopathies.
The two companies will make as much as $200 million on combined investment by 2018, Sanofi said.
-Write to Inti Landauro at firstname.lastname@example.org
Subscribe to WSJ: http://online.wsj.com?mod=djnwires